tiprankstipranks

Ben Gil Price Insider Profile

4 Followers
Ben Gil Price, Director at Sarepta Therapeutics, holds 15.00K shares in Opus Genetics (Ticker: IRD), holds 37.33K shares in Sarepta Therapeutics (Ticker: SRPT), holds ― shares in MetaVia (Ticker: MTVA). Most recently, Ben Gil Price Bought ― shares of Opus Genetics on Jan 31, 2019 for an estimated value of 9.00K.
tipranks
Ben Gil Price

Ben Gil Price
Sarepta Therapeutics (SRPT)
Director

Ranked #40,373 out of 99,797 Corporate Insiders

Profitable Transactions

50%
1 out of 2 Profitable Transactions

Average Return

+17.50%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark

Insider Holdings

$4M
99.67%
0.33%
0.00%
A breakdown of Ben Gil Price's holdings

Insider Roles

Sarepta Therapeutics
(SRPT)
Director
Opus Genetics
(IRD)
Director
MetaVia
(MTVA)
CEO and President
Roles that Ben Gil Price holds in companies

Most Profitable Insider Trade

Stock:
Sarepta Therapeutics
(SRPT)
Rating:Informative Buy
Date:Mar 16, 2016 - Mar 16, 2017
Return:+108.50%
The most profitable trade made by Ben Gil Price

Ben Gil Price's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
Sarepta Therapeutics
Mar 16, 2016
Director
Informative Buy
75.11K
$4.44M
Opus Genetics
Jan 31, 2019
Director
Informative Buy
9.00K
$14.67K
MetaVia
CEO and President
List of latest transactions for each holding click on a transaction to see Ben Gil Price's performance on stock

Ben Gil Price insider profile FAQ

What is the percentage of profitable transactions made by Ben Gil Price?
The percentage of profitable transactions made by Ben Gil Price is 50%.
    What is the average return per transaction made by Ben Gil Price?
    The average return per transaction made by Ben Gil Price is 17.50%.
      What stocks does Ben Gil Price hold?
      Ben Gil Price holds: SRPT, IRD, MTVA stocks.
        What was Ben Gil Price’s latest transaction?
        Ben Gil Price latest transaction was an Informative Buy of $9.00K.
          What was Ben Gil Price's most profitable transaction?
          Ben Gil Price’s most profitable transaction was an Informative Buy of SRPT stock on March 16, 2016. The return on the trade was 108.50%.
            What is Ben Gil Price's role in Sarepta Therapeutics?
            Ben Gil Price's role in Sarepta Therapeutics is Director.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.